Black Diamond Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BDTX and other ETFs, options, and stocks.

About BDTX

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases.

CEO

Mark A. Velleca

CEOMark A. Velleca

Employees

Employees24

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2014

Founded2014

Employees

Employees24

BDTX Key Statistics

Market cap

148.99M

Market cap148.99M

Price-Earnings ratio

7.08

Price-Earnings ratio7.08

Dividend yield

—

Dividend yield—

Average volume

846.12K

Average volume846.12K

High today

$2.60

High today$2.60

Low today

$2.60

Low today$2.60

Open price

$2.58

Open price$2.58

Volume

1.14K

Volume1.14K

52 Week high

$4.94

52 Week high$4.94

52 Week low

$1.20

52 Week low$1.20

Stock Snapshot

As of today, Black Diamond Therapeutics(BDTX) shares are valued at $2.60. The company's market cap stands at 148.99M, with a P/E ratio of 7.08.

As of 2026-01-07, Black Diamond Therapeutics(BDTX) stock has fluctuated between $2.60 and $2.60. The current price stands at $2.60, placing the stock 0.0% above today's low and 0.0% off the high.

The Black Diamond Therapeutics(BDTX)'s current trading volume is 1.14K, compared to an average daily volume of 846.12K.

During the past year, Black Diamond Therapeutics(BDTX) stock moved between $1.20 at its lowest and $4.94 at its peak.

Analyst ratings

89%

of 9 ratings

Buy

88.9%

Hold

11.1%

Sell

People also own

Based on the portfolios of people who own BDTX. This list is generated using Robinhood data, and it’s not a recommendation.